cilostamide has been researched along with Heart Failure in 6 studies
cilostamide: selective inhibitor of cyclic AMP phosphodiesterase & platelet aggregation; structure
Heart Failure: A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The β-blockers carvedilol and metoprolol provide important therapeutic strategies for heart failure treatment." | 3.80 | Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium. ( Berk, E; Christ, T; Engel, A; Galindo-Tovar, A; Gillette, KT; Kaumann, AJ; Molenaar, P; Ravens, U, 2014) |
| "Heart failure was induced in male Wistar rats by coronary artery ligation." | 1.36 | Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition. ( Aronsen, JM; Hougen, K; Levy, FO; Moltzau, LR; Nguyen, CH; Osnes, JB; Qvigstad, E; Sjaastad, I; Skomedal, T, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Orstavik, O | 1 |
| Ata, SH | 1 |
| Riise, J | 1 |
| Dahl, CP | 1 |
| Andersen, GØ | 1 |
| Levy, FO | 3 |
| Skomedal, T | 3 |
| Osnes, JB | 3 |
| Qvigstad, E | 2 |
| Molenaar, P | 1 |
| Christ, T | 1 |
| Berk, E | 1 |
| Engel, A | 1 |
| Gillette, KT | 1 |
| Galindo-Tovar, A | 1 |
| Ravens, U | 1 |
| Kaumann, AJ | 1 |
| Hubert, F | 1 |
| Belacel-Ouari, M | 1 |
| Manoury, B | 1 |
| Zhai, K | 1 |
| Domergue-Dupont, V | 1 |
| Mateo, P | 1 |
| Joubert, F | 1 |
| Fischmeister, R | 1 |
| Leblais, V | 1 |
| Moltzau, LR | 1 |
| Aronsen, JM | 2 |
| Nguyen, CH | 1 |
| Hougen, K | 1 |
| Sjaastad, I | 2 |
| Hussain, RI | 1 |
| Afzal, F | 1 |
| Krobert, KA | 1 |
| Tarpey, SB | 1 |
| Sawmiller, DR | 1 |
| Kelly, C | 1 |
| Thompson, WJ | 1 |
| Townsley, MI | 1 |
6 other studies available for cilostamide and Heart Failure
| Article | Year |
|---|---|
Inhibition of phosphodiesterase-3 by levosimendan is sufficient to account for its inotropic effect in failing human heart.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiotonic Agents; Heart; Heart Failure; Humans; Hydraz | 2014 |
Carvedilol induces greater control of β2- than β 1-adrenoceptor-mediated inotropic and lusitropic effects by PDE3, while PDE4 has no effect in human failing myocardium.
Topics: Adrenergic beta-Antagonists; Adult; Carbazoles; Carvedilol; Cyclic Nucleotide Phosphodiesterases, Ty | 2014 |
Alteration of vascular reactivity in heart failure: role of phosphodiesterases 3 and 4.
Topics: Adrenergic beta-Agonists; Animals; Aorta, Thoracic; Cyclic Nucleotide Phosphodiesterases, Type 3; Cy | 2014 |
Natriuretic peptides increase beta1-adrenoceptor signalling in failing hearts through phosphodiesterase 3 inhibition.
Topics: Animals; Apoptosis; Cyclic AMP; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Cyclic Nucleotide | 2010 |
The functional activity of inhibitory G protein (G(i)) is not increased in failing heart ventricle.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Carbachol; Cardiotonic Agents; GTP-Binding Pro | 2013 |
Phosphodiesterase 3 activity is reduced in dog lung following pacing-induced heart failure.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Capillaries; Capillary Permeability; Colforsin; Cyclic | 2003 |